Gene · 22925
Papers2,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Optimization of a Target Antigen Diagnostic Pathway for Membranous Nephropathy. | Kidney Int Rep | 2026 | 42305256 | PubTator, text mining | PubMed |
| Transcriptomic analysis of differential expression and correlation of coding and non-coding RNAs in urine from patients with idiopathic membranous nephropathy. | Biol Direct | 2026 | 42304425 | PubTator, text mining | PubMed |
| In Reply: Reassessing Cancer Attribution and Methodologic Limitations in PLA2R-Associated Membranous Nephropathy. | Mayo Clin Proc | 2026 | 42297139 | PubTator, text mining | PubMed |
| Sensitive detection of anti-PLA2R antibodies for idiopathic membranous nephropathy diagnosis via carbon paper@black phosphorus@silver nanocomposites-based sandwich immunoassay. | Talanta | 2026 | 42296871 | PubTator, text mining | PubMed |
| Identification of antibodies against phospholipase A2 receptor peptides in PLA2R-associated membranous nephropathy with negative circulating anti-PLA2R antibodies. | Front Immunol | 2026 | 42292419 | PubTator, text mining | PubMed |
| A machine learning model integrating two-dimensional ultrasound radiomics and clinical parameters for differentiating membranous nephropathy from IgA nephropathy. | J Ultrasound | 2026 | 42277408 | PubTator, text mining | PubMed |
| Reassessing Cancer Attribution and Methodologic Limitations in PLA2R-Associated Membranous Nephropathy. | Mayo Clin Proc | 2026 | 42276523 | PubTator, text mining | PubMed |
| Serum anti-PLA2R negativity does not exclude glomerular PLA2R expression in primary membranous nephropathy. | Biomol Biomed | 2026 | 42267385 | PubTator, text mining | PubMed |
| Discovery of endothelial cell antibodies associated with pediatric and adult kidney allograft rejection and assessment of a non-human leukocyte antigen antibody assay. | Am J Transplant | 2026 | 42264037 | PubTator, text mining | PubMed |
| Rituximab vs. cyclophosphamide in treatment-naive IMN: efficacy and renal protection in early renal impairment. | Clin Exp Nephrol | 2026 | 42258058 | PubTator, text mining | PubMed |
| The value of proteinuria for the administration of rituximab in patients with PLA2R-associated membranous nephropathy: a single-centre retrospective analysis. | Ann Med | 2026 | 42247284 | PubTator, text mining | PubMed |
| Obinutuzumab is effective for refractory primary membranous nephropathy. | BMC Nephrol | 2026 | 42231213 | PubTator, text mining | PubMed |
| Whole genome-based polygenic risk score and structural variation analysis in Korean patients with inflammatory bowel disease. | BMB Rep | 2026 | 42226727 | PubTator, text mining | PubMed |
| Protocadherin 7 Positive Membranous Nephropathy in China. | Nephrol Dial Transplant | 2026 | 42172092 | PubTator, text mining | PubMed |
| Living Donor Kidney Transplantation in High-Recurrence Kidney Diseases: Precision Risk Stratification and Management. | Kidney Int Rep | 2026 | 42164636 | PubTator, text mining | PubMed |
| Development and clinical application of a highly sensitive serological assay for detecting thrombospondin type-1 domain-containing 7A antibodies in idiopathic membranous nephropathy. | J Immunol Methods | 2026 | 42162779 | PubTator, text mining | PubMed |
| Anti-Obinutuzumab Antibodies in Primary Membranous Nephropathy. | Nephrol Dial Transplant | 2026 | 42153617 | PubTator, text mining | PubMed |
| Is Rituximab Suitable for Patients with Idiopathic Membranous Nephropathy Who are Seronegative for Anti-PLA2R Antibody? | Drug Des Devel Ther | 2026 | 42152814 | PubTator, text mining | PubMed |
| Anti-PLA2R antibodies promote endothelial pyroptosis and a procoagulant phenotype through FcγRI signaling. | Nephrol Dial Transplant | 2026 | 42127088 | PubTator, text mining | PubMed |
| Serum Phospholipase A2 Receptor Antibody Is Associated with Thrombogenesis in Primary Membranous Nephropathy: A Systematic Review and Meta-Analysis. | Glomerular Dis | 2026 | 42111655 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/22925/papers?page=3